Insuman Comb 50 (Insulin Human)

Insulin human is a synthetic version of the body’s natural insulin. It binds to insulin receptors on muscle, fat and liver cells, activating a signaling cascade that promotes glucose uptake, storage as glycogen, and reduces hepatic glucose production, thereby lowering blood glucose levels.

The dose of Insuman Comb 50 is individualized by the prescribing healthcare professional based on the patient’s blood glucose readings, diet, activity level and overall treatment goals. Patients should follow the dosing regimen set by their prescriber and adjust only under medical supervision.

Insulin is generally considered the treatment of choice for diabetes during pregnancy because it does not cross the placenta in harmful amounts. However, the safety of Insuman Comb 50 specifically should be evaluated by a healthcare provider, and the benefits must outweigh any potential risks.

To order Insuman Comb 50, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Insuman Comb 50 is a premixed 1:1 combination of soluble (rapid‑acting) and isophane (intermediate‑acting) insulin, offering the convenience of a single daily injection for patients who need both basal and prandial coverage. Compared with basal‑only or rapid‑acting‑only insulins, it reduces injection frequency but provides less flexibility for precise dose adjustments.

Store Insuman Comb 50 at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. If needed for short‑term use, it may be kept at controlled room temperature (up to 25 °C) for a maximum of 28 days, but refrigeration is preferred.

Insuman Comb 50 is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated with each dose to reduce the risk of lipodystrophy. Patients must be trained on proper technique, needle length, and timing relative to meals.

The most serious risks include severe hypoglycemia, which can lead to seizures, loss of consciousness or coma, and allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical help if a severe reaction occurs.

Insuman Comb 50 should not be used by individuals with a known hypersensitivity to human insulin or any of the excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia at the time of administration. Clinical judgment is required for patients with certain endocrine disorders or severe renal impairment.